Skip to main content

August 2018 Vol 11, Special Issue

Conference Highlights ASCO, Introduction
Precision Medicine and Immunotherapy Highlighted at ASCO 2018
Wayne Kuznar
Read More
FDA Approvals
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation
Phoebe Starr
Read More
FDA Approvals
LOXO-292 Highly Effective in RET-Positive Cancers
Chase Doyle
Read More
FDA Approvals
FDA Approvals, News & Updates - August 2018
Read More
Cell-Free DNA Assays Could Result in a New Blood Test for Early Detection of Cancer
Wayne Kuznar
Read More
Immunotherapy, Oncology
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Immunotherapy, Oncology
Immunotherapy Combinations "Raising the Bar"
Phoebe Starr
Read More
Breast Cancer, Oncology
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
Read More
Breast Cancer, Oncology
First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer
Chase Doyle
Read More
IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer
Wayne Kuznar
Read More
Page 2 of 3
Results 11 - 20 of 24